Abstract: Up to 10% of cases of gastric cancer are familial, but so far, only mutations in CDH1 have been associated with gastric cancer risk. To identify genetic variants that affect risk for gastric cancer, we collected blood samples from 28 patients with hereditary diffuse gastric cancer (HDGC) not associated with mutations in CDH1 and performed whole-exome sequence analysis.
We then analyzed sequences of candidate genes in 333 independent HDGC and non-HDGC cases. We identified 11 cases with mutations in PALB2, BRCA1, or RAD51C genes, which regulate homologous DNA recombination. We found these mutations in 2 of 31 patients with HDGC (6.5%) and 9 of 331 patients with sporadic gastric cancer (2.8%). Most of these mutations had been previously associated with other types of tumors and partially co-segregated with gastric cancer in our study. Tumors that developed in patients with these mutations had a mutation signature associated with somatic homologous recombination deficiency. Our findings indicate that defects in homologous recombination increase risk for gastric cancer.
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Worldwide, gastric cancer (GC) is the fifth most commonly diagnosed malignancy and the third cause of cancer-related deaths 1 . Up to 10% of cases show familial clustering, suggesting a genetic basis 2 . CDH1 mutations are a known cause of hereditary diffuse gastric cancer (HDGC), explaining ~ 40% of cases 3, 4 , but the genetics of non-HDGC remain largely unknown. To identify novel GC genes, we analyzed CDH1 mutation-negative HDGC cases using whole exome sequencing (WES) followed by candidate gene targeted analyses in independent HDGC and non-HDGC cases.
WES of 28 CDH1-negative European HDGC cases identified three with candidate causal variants (Table 1) : nonsense (p.Arg414Ter) and splice site (c.3201+1G>T) PALB2 mutations, and a nonsense RAD51C (p.Arg237Ter) mutation. No deleterious mutations were seen in other known cancer genes (Supplementary methods). PALB2 and RAD51C are both critical in homologous recombination (HR), a major DNA repair pathway 5 . Both of the above PALB2 mutations have been previously reported as pathogenic in breast cancer (BC) families 6 and RAD51C p.Arg237Ter is reported as pathogenic in ClinVar 7 .
We then performed targeted sequencing of PALB2 and RAD51C, their interaction partners BRCA1/2 and CDH1 in 173 additional Latin American GC cases. Based upon enrichment of HR mutations in our discovery cohort and a recent report showing multiple intestinal, diffuse and mixed histology gastric tumors with a somatic HR deficiency signature 8 , our validation cohort included both HDGC and non-HDGC cases of diffuse and non-diffuse histology (Supplementary methods). Targeted sequencing identified four additional mutation carriers: two sharing a known Hispanic BRCA1 founder mutation (p.Gln1111Asnfs) 9 and two with novel PALB2 mutations (p.Pro918Gln and p.Lys628_Cys630del) with predicted deleterious effects. Residue Pro918 falls in the PALB2 WD40 domain, which mediates interactions with BRCA2, RAD51 and RAD51C, whereas Lys628-Cys630 resides in the binding domain of MRG15, a transcription regulator and whose PALB2 interaction is required for homology directed DNA double-strand break repair indicating potential pathogenicity of these two novel mutations 10, 11 .
In a third phase of the study, we genotyped all six PALB2, RAD51C and BRCA1 mutations described above plus four known Hispanic BRCA1/2 founder mutations (Supplementary methods) in 160 independent Latin American non-HDGC cases and found three additional mutation carriers, one with a BRCA1 mutation (p.Gly559Valfs) and two with PALB2 mutations (p.Lys628_Cys630del and p.Arg414Ter, Table 1 ). Interestingly, during the preparation of this manuscript, our clinic-based Portuguese collaborator (MT), identified one additional GC case (GM037589) with PALB2 p.Arg414Ter.
None of the seven PALB2, RAD51C and BRCA1 mutations, detected in 11 unrelated Caucasian and Latin American cases, was detected in 1,170 population-matched controls (see mutation details in Supplementary Table 1 ).
Clinical details of our mutation carriers are given in Table 1 . Most of them had diffuse histology, two had HDGC syndrome (CG-05 and GM022584) and one reported history of hereditary breast and ovarian cancer (HBOC, case CG-36, not shown). These mutation carriers were predominantly non-smokers and/or negative for Helicobacter pylori infection (Table 1) , which suggest that GC risk in most of these cases was not driven by these two known environmental risk factors 12 .
To obtain additional evidence of the causality of our HR gene mutations, we carried out loss of heterozygosity (LOH), mutational signature and co-segregation analyses in available samples from tumors and relatives. For LOH and mutational signatures, we performed WES in four available tumor samples from three PALB2 (CG-12/p.Arg414Ter, CG-028/p.Lys628_Cys630del and 3CG-103/p.Pro918Gln) and RAD51C mutation carriers (Table 1) . We found no LOH or compound heterozygosity in these tumor samples (not shown). Interestingly, when we analyzed the somatic WES data for mutational signatures, we found that all four tumors were enriched for a signature indicative of HR defects 13, 14 , providing evidence for the causality of these mutations (Supplementary methods, Figure 1A ). GM037589, a PALB2 p.Arg414Ter carrier, developed GC and BC and had a sister diagnosed with ovarian and endometrial cancer who also carried PALB2 p.Arg414Ter ( Figure 1B) . The RAD51C p.Arg237Ter carrier's son died of colon cancer but did not carry the mutation ( Figure 1C ). We found that GC was the predominantly diagnosed malignancy among unavailable relatives of these carriers ( Figures 1A-1D ). Although we did not have access to samples from relatives of the PALB2 p.Lys628_Cys630del carriers, our local collaborators found this mutation co-segregating in an unrelated breast cancer family (unpublished).
Albeit limited, our co-segregation data partially support GC causality of PALB2 mutations. The RAD51C co-segregation data is however inconclusive but the presence of a strong HR signature in the gastric tumor (see above) of this mutation carrier warrants further studies on RAD51C as a candidate GC gene.
In summary, our study identified eleven cases with mutations in PALB2, BRCA1 and RAD51C, three closely-related HR genes. Some of these mutations are known to be pathogenic in other cancer types. Out of 362 cases analyzed, 6.45% of the HDGC cases (2 out of 31) and 2.7% (9 out of 331) of non-HDGC cases had PALB2, BRCA1 or RAD51C mutations, suggesting that HR genes play a role in GC risk.
Our data also provide evidence of a germline basis for the recently reported HR mutational signature in gastric tumors and strengthens the evidence for a causal role of these genes, specifically PALB2, in GC, as previously observed 4, 15 . Future larger studies are needed to definitively assign causality and understand the penetrance and prevalence of HR gene mutations in GC and to further understand if and why some individuals from HBOC families with HR gene mutations develop GC. Further characterizations of the GC histology in HR gene mutation carriers are also needed as we found instances where the same mutation was found in cases with different histologies (CG-12 and CG-008 with PALB2 p.Arg414ter and CG-039 and CG-028 with PALB2 p.Lys628_Cys630del, Table 1 ). CDH1 mutation negative families might benefit from HR gene testing and increased endoscopic surveillance and targeted therapies, such as PARP inhibitors 8 .
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WES library preparation:
Targeted sequencing library preparation and data analysis: ~350bp PCR amplicons covering
the entire coding regions of BRCA1, BRCA2, CDH1, PALB2 and RAD51C were amplified from 50ng of genomic DNA using Fluidigm Access array system and libraries were sequenced on a MiSeq platform with 250PE reads. Sequence data analysis was performed with a bioinformatics pipeline similar to the one described for WES above. ACCAACCAAACGTAACTTTACTCAA.
Phase III -Mutation validation by genotyping
WES of tumor DNA for loss of heterozygosity (LOH) and mutational signature analysis
DNA was extracted, using a Qiagen tissue kit, from formalin fixed paraffin embedded (FFPE) tumor tissue samples from four cases: CG-12 (PALB2 nonsense mutation carrier), 3CG-103 (PALB2 missense mutation carrier), CG-028 (PALB2 in-frame deletion carrier) and GM022584
(RAD51C nonsense mutation carrier). WES was performed using KAPA and Agilent SureSelect PE150 sequencing. Sequence data analysis was performed using GATK best practices as described above and somatic variants were called with GATK MuTect2 15 .
Mutational signature analysis: Mutational signature analysis in somatic tissue is a recent field that is undergoing active development, improvement and statistical grounding. The first general signature model for mutation signature analysis was developed by Alexandrov et al 16 Figure 1A and 1B Figure 1C ). Tumor DNA from our study samples was derived from FFPE tissue, and was thus expected to have a higher percentage of C: G>T: A mutations. Therefore we analyzed mutational signatures after removing C:G>T:A from our study samples as well as from control samples (restricted analysis). Similar to the full analysis, we first identified signatures with high Frobenius similarity to Shiraishi HR signatures, using K=3 (Supplementary Figure 1D) . After optimizing the method, we proceeded to determine whether an HR signature was demonstrated by the four study samples where somatic WES data was available (see above). As shown in Supplementary   Figure 2 , our study samples as well as the TCGA positive controls, at K=3, in full and restricted analysis have a significantly higher relative contribution or membership weight for the HR signature compared to the negative controls. Interestingly, another hallmark of somatic HR deficiency is a high frequency of large indels 16, 19 . Consistently, similar to TCGA HR-positive controls, the mean deletion length found in the tumors from our four PALB2/RAD51C mutation carriers was higher than in TCGA nonHR GC cases (31.6 bp vs. 15.4 bp, P= 3 x 10 -7 ). 
